Background Antiphospholipid antibodies targeting β 2-glycoprotein I (β 2 GPI) cause
thrombosis and pregnancy morbidity in antiphospholipid syndrome (APS) patients. How …

Summary β 2‐Glycoprotein I (β 2‐GPI) is a protein that circulates in blood at high
concentrations. The function of β 2‐GPI has long been an enigma. More than 20 years ago …

β 2-Glycoprotein I (β 2 GPI) is an abundant plasma protein displaying phospholipid-binding
properties. Because it binds phospholipids, it is a target of antiphospholipid antibodies …

Antiphospholipid antibodies (aPL), the serological hallmark of antiphospholipid syndrome
(APS), are a heterogeneous group of autoantibodies raised against circulating blood …

Antibodies against β2 glycoprotein I (anti-β2GPI) have been identified as the main
pathogenic autoantibody subset in anti-phospholipid syndrome (APS); the most relevant …

INTRODUCTION: Antiphospholipid Syndrome (APS) is characterized by the presence of
circulating antiphospholipid antibodies in patients with thrombosis or pregnancy morbidity …

Abstract Beta-2 glycoprotein I (β 2 GPI) is the main antigenic target for antiphospholipid
antibodies (aPL), the serological markers of antiphospholipid syndrome (APS). Domain I (DI) …

Antiphospholipid syndrome (APS) is an autoimmune thrombophilia characterized by
arterial/venous thrombosis and/or pregnancy morbidity in the presence of antiphospholipid …

The presence of antiphospholipid antibodies (aPL) is strongly correlated with venous and
arterial thrombosis, fetal loss and thrombocytopenia. This relation is called the …

β2-Glycoprotein I (β2GPI), a phospholipid-binding protein, is one of the major target
antigens for antiphospholipid antibodies (aPL) found in patients with antiphospholipid …